Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

ABSTRACT:

Background

Mesenchymal stem cells (MSCs) exhibit immunomodulatory, tissue-protective, and repair-promoting properties in vitro and in animals. Clinical trials in several human conditions support the safety and efficacy of MSC transplantation. Published experience in multiple sclerosis (MS) is modest.

Objective

To assess feasibility, safety, and tolerability and explore efficacy of autologous MSC transplantation in MS.

Methods

Participants with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS), Expanded Disability Status Scale score 3.0-6.5, disease activity or progression in the prior 2 years, and optic nerve involvement were enrolled. Bone-marrow-derived MSCs were culture-expanded and then cryopreserved. After confirming

SUBMITTER: Cohen JA 

PROVIDER: S-EPMC5623598 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature